Jasper Therapeutics (NASDAQ:JSPR) Earns “Buy” Rating from HC Wainwright

Jasper Therapeutics (NASDAQ:JSPR)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $40.00 price objective on the stock.

Other equities research analysts have also issued research reports about the company. BMO Capital Markets initiated coverage on Jasper Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target on the stock. Royal Bank of Canada decreased their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday, January 9th. JMP Securities restated a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. Finally, UBS Group began coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They issued a “buy” rating and a $38.00 price objective on the stock. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $62.50.

Jasper Therapeutics Trading Down 2.3 %

NASDAQ:JSPR traded down $0.12 during mid-day trading on Tuesday, hitting $5.16. 146,788 shares of the company’s stock were exchanged, compared to its average volume of 657,280. Jasper Therapeutics has a fifty-two week low of $4.55 and a fifty-two week high of $31.01. The firm has a market capitalization of $77.45 million, a P/E ratio of -1.09 and a beta of 2.23. The company has a 50 day simple moving average of $7.99 and a 200-day simple moving average of $16.28.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.35). As a group, analysts expect that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its stake in Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after purchasing an additional 1,698 shares in the last quarter. MetLife Investment Management LLC increased its position in Jasper Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after buying an additional 3,873 shares in the last quarter. Wells Fargo & Company MN raised its stake in Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after buying an additional 3,828 shares during the period. EntryPoint Capital LLC acquired a new position in Jasper Therapeutics during the 4th quarter worth approximately $223,000. Finally, Jane Street Group LLC bought a new position in Jasper Therapeutics in the third quarter worth approximately $251,000. 79.85% of the stock is owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.